Biolyst › PRQRProQR Therapeutics N.V. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
No upcoming catalysts are currently on record for PRQR. Past events are listed below.
Upcoming catalysts
Nothing scheduled.
Track PRQR alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open PRQR in the tracker
Recent history
Date Event Type Phase
September 23, 2026
6-K filed: Foreign issuer report Filing
—
September 9, 2026
6-K filed: Foreign issuer report Filing
—
August 13, 2026
6-K filed: Foreign issuer report Filing
—
August 13, 2026
6-K filed: Foreign issuer report Filing
—
June 26, 2026
6-K filed: Foreign issuer report Filing
—
June 25, 2026
6-K filed: Foreign issuer report Filing
—
June 2, 2026
6-K filed: Foreign issuer report Filing
—
May 12, 2026
6-K filed: Foreign issuer report Filing
—
May 12, 2026
6-K filed: Foreign issuer report Filing
—
May 4, 2026
6-K filed: Foreign issuer report Filing
—
April 30, 2026
6-K filed: Foreign issuer report Filing
—
April 8, 2026
6-K filed: Foreign issuer report Filing
—
April 8, 2026
6-K filed: Foreign issuer report Filing
—
March 25, 2026
6-K filed: Foreign issuer report Filing
—
March 12, 2026
6-K filed: Foreign issuer report Filing
—
March 12, 2026
Results filed (20-F) Earnings
—
February 9, 2026
6-K filed: Foreign issuer report Filing
—
January 8, 2026
6-K filed: Foreign issuer report Filing
—
November 6, 2025
6-K filed: Foreign issuer report Filing
—
November 3, 2025
6-K filed: Foreign issuer report Filing
—
October 20, 2025
6-K filed: Foreign issuer report Filing
—
August 7, 2025
6-K filed: Foreign issuer report Filing
—
June 26, 2025
6-K filed: Foreign issuer report Filing
—
June 3, 2025
6-K filed: Foreign issuer report Filing
—
May 8, 2025
6-K filed: Foreign issuer report Filing
—
May 1, 2025
6-K filed: Foreign issuer report Filing
—
April 14, 2025
6-K filed: Foreign issuer report Filing
—
June 7, 2022
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene Trial Milestone
Phase 1/Phase 2
January 31, 2022
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) Trial Milestone
Phase 2/Phase 3
October 14, 2021
Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene Trial Milestone
Phase 1/Phase 2
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.